Item 8.01 Other Events.

On January 9, 2023, Ocugen, Inc. issued a press release announcing positive top-line data from the Phase 2/3 immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™ (BBV152). A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are being filed herewith:



(d) Exhibits

Exhibit No.                Document
99.1                         Press Release of Ocugen, Inc. dated January 9, 2023.
                           Cover Page Interactive Data File (embedded within the Inline XBRL
104                        document).


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses